Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma

Neurology

Volumn 77, Issue 6, 2011, Pages 532-539

  De Groot, M ^a,b   Aronica, E ^b,c   Heimans, J J ^a   Reijneveld, J C ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ETIRACETAM; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; NOOTROPIC AGENT; PIRACETAM; SV2A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; DRUG EFFICACY; EPILEPSY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OPTICAL DENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE; BRAIN TUMOR; COHORT ANALYSIS; GENETICS; LABORATORY DIAGNOSIS; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BRAIN NEOPLASMS; COHORT STUDIES; EPILEPSY; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NOOTROPIC AGENTS; PIRACETAM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053312809     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318228c110     Document Type: Article

References (32)

1. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-430.
2. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005;65:212-215.
3. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003;54:514-520.
4. Lynam LM, Lyons MK, Drazkowski JF, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007;109:634-638.
5. Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998;17:479-482.
6. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893.
7. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
8. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866.
9. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006;536:102-108.
10. Janz R, Goda Y, Geppert M, Missler M, Sudhof TC. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 1999;24:1003-1016.
11. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006;26:1303-1313.
12. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 1999;96:15268-15273.
13. De Groot M, Toering ST, Boer K, et al. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro Oncol 2010;12:265-273.
14. Kinirons P, McCarthy M, Doherty CP, Delanty N. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 2006;15:387-392.
15. Neugebauer R. Reliability of seizure diaries in adult epileptic patients. Neuroepidemiology 1989;8:228-233.
16. Ravizza T, Boer K, Redeker S, et al. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006;24:128-143.
17. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis 2007;26:497-511.
18. Aronica E, Redeker S, Boer K, et al. Inhibitory networks in epilepsy-associated gangliogliomas and in the perilesional epileptic cortex. Epilepsy Res 2007;74:33-44.
19. van Linde, ME, Verhoeff J J C, Stalpers L J A, Reijneveld JC, van Furth WR, Richel DJ. Feasibility of combined treatment with bevacizumab, radiotherapy and temozolomide in resectable and irresectable newly diagnosed glioblastoma multiforme. Neuro-Oncology 2009;628. Abstract
20. Wilhelm A, Volknandt W, Langer D, Nolte C, Kettenmann H, Zimmermann H. Localization of SNARE proteins and secretory organelle proteins in astrocytes in vitro and in situ. Neurosci Res 2004;48:249-257.
21. Wharton SB, Chan KK, Whittle IR. Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci 2002;9:165-169.
22. Wharton SB, Chan KK, Hamilton FA, Anderson JR. Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol 1998;24:302-308.
23. Kaminski RM, Gillard M, Leclercq K, et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009;50:1729-1740.
24. Lynch JM, Tate SK, Kinirons P, et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res 2009;83:44-51.
25. Nagarkatti N, Deshpande LS, De Lorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett 2008;436:289-293.
26. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-671.
27. Stienen MN, Haghikia A, Dambach H, et al. Antiinflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFss1 regulation. Br J Pharmacol 2011;162:491-507.
28. Kim JE, Choi HC, Song HK, et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci Lett 2010;471:94-99.
29. Haghikia A, Ladage K, Hinkerohe D, et al. Implications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocytes. J Neurosci Res 2008;86:1781-1788.
30. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108:227-235.
31. Quigg M, Barbaro NM. Stereotactic radiosurgery for treatment of epilepsy. Arch Neurol 2008;65:177-183.
32. Schrottner O, Eder HG, Unger F, Feichtinger K, Pendl G. Radiosurgery in lesional epilepsy: brain tumors. Stereotact Funct Neurosurg 1998;70(suppl 1): 50):50-56.